ArticleInflammopharmacology2026
Ruxolitinib phosphate-laden nanoemulgel: amelioration of ex vivo permeation and in vivo therapeutic efficacy for the effective therapeutic management of psoriasis.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic, immune-driven inflammatory skin ailment marked by recurrent flare-ups. Ongoing clinical investigations are focused on therapeutic strategies that modulate key signaling pathways implicated in disease pathogenesis. Ruxolitinib (RUX) is a Janus kinase 1/2 inhibitor approved for several hematological and inflammatory disorders, is being clinically investigated as a potential therapeutic option for psoriasis. The current study reports the formulation, characterization, and assessment of in vitro, ex vivo, and in vivo efficacy of RUX-loaded nanoemulgel (RUX NEG) for the management of psoriasis. The spontaneous emulsification method was employed to prepare RUX-loaded nanoemulsion, which has shown a droplet size of 50.35 ± 1.05 nm with a polydispersity index of 0.20 ± 0.01. Further, RUX-loaded nanoemulsion incorporated in a gel matrix to form a RUX-NEG that has shown pseudoplastic shear thinning behaviour. Meanwhile, ex vivo permeation of RUX-NEG demonstrated steady-state flux and significantly higher retention (74.12 ± 13.56 µg/g) of RUX in epidermal skin layers than that of plain gel (52.39 ± 8.69 µg/cm
Indexed as
Identifiers
42283802What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.